Following their debate on approaches to early phase management of refractory status epilepticus (RSE), Salia Farrokh, PharmD is joined by Caroline Der Nigoghossian, Neurocritical Care PharmD, Renad Abu-Sawwa, PharmD, and Gabe Fontaine, PharmD to explore the benefits and harms/risks of early ketamine administration in refractory status epilepticus, as well as the emerging literature for the use of ketamine in pediatric neurocritical care.